Company
Every investor coverage indicates participated in a round Institut de Cancérologie de l'Ouest (ICO) raised.
Companies Institut de Cancérologie de l'Ouest (ICO) acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Caroline Rousseau | Principal Investigator | Forbes Australia |
Stories naming Institut de Cancérologie de l'Ouest (ICO). Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Telix, an ASX-listed radiopharmaceutical maker headquartered in Melbourne, is preparing a dual US listing; the piece also covers revenue growth, cancer trial results and recalls its 2017 float.